Hims & Hers Health announced the appointment of Nader Kabbani, a former Amazon executive, as its new chief operations officer. Kabbani, who spent nearly two decades at Amazon, played a key role in launching various health-care initiatives, including Amazon Pharmacy, the acquisition of PillPack, and the company’s global Covid-19 Vaccination Task Force. He was also instrumental in the development of Amazon Kindle, Amazon Logistics, and the launch of Amazon Music and Prime Video services. With his extensive experience in scaling operations, Kabbani is expected to help Hims & Hers continue its growth and expansion.
Hims & Hers, a telehealth company that offers a wide range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, has seen its revenue grow by 69% in the past year. The company is focused on making healthcare more accessible through online platforms, and Kabbani’s expertise is seen as crucial to enhancing its operational capabilities. Andrew Dudum, the CEO of Hims & Hers, praised Kabbani’s experience, noting that his leadership will be instrumental in shaping the company’s future in the healthcare sector.
In addition to his time at Amazon, Kabbani has also held leadership positions at Flexport, a supply chain logistics company, and Symbotic, a warehouse automation firm. His diverse background is expected to bring valuable insights to Hims & Hers as it navigates the evolving healthcare market. The company has faced a volatile stock performance this year, with its share price fluctuating significantly in response to various factors. One of the key areas of investor focus has been Hims & Hers’ weight loss offering, which faced uncertainty earlier in the year when the U.S. Food and Drug Administration announced changes to the medication supply landscape.
Despite the challenges, Hims & Hers’ stock has seen impressive growth, with shares increasing by more than 70% year to date. The company’s stock rose sharply in April after Novo Nordisk announced that it would offer its weight loss drug Wegovy through telehealth providers, including Hims & Hers. The company is set to report its earnings after market close, with investors eagerly awaiting the next update on its financial performance.
READ MORE: